jeudi 3 décembre 2020


Cerus Announces National German Reimbursement for Pathogen Inactivated Platelets

Par Rédaction , dans Communiqués , le 15 novembre 2017

Monday, October 23rd 2017 at 12:30pm UTC

CONCORD, Calif.–(BUSINESS WIRE)– Cerus Corporation (NASDAQ:CERS) announced today that the Institute for
the Hospital Remuneration System (Institut für das Entgeltsystem im
Krankenhaus, or InEK) in Germany will include pathogen-inactivated
platelets for national reimbursement starting January 1, 2018.
Pathogen-inactivated platelets will be reimbursed through ZE
(Zusatzentgelte) codes 164 and 165 and cover both platelet collection
methods currently in use in Germany, apheresis and whole blood derived
buffy coat platelets. The INTERCEPT Blood System is the only pathogen
inactivation system currently approved in Germany for treatment of
platelets.

The national reimbursement codes for pathogen-inactivated platelets
allow German hospitals to recoup the costs of INTERCEPT platelets at a
premium price over untreated platelet units. With approximately 575,000
platelets produced each year in Germany, the German market is the
largest in Europe. Four German Red Cross blood services manufacture
approximately 45% of the platelets used each year. In total, there are
approximately 60 blood banks and self-collecting university hospitals in
Germany.

“InEK’s decision to provide national reimbursement for
pathogen-inactivated platelets is a pivotal public health policy change
that could improve patient access to platelets with a reduced risk of
transfusion transmitted infection,” commented William ‘Obi’ Greenman,
Cerus’ president and chief executive officer.

German blood and blood products are regulated by the Paul Ehrlich
Institute (PEI), the Federal Institute for Vaccines and Biomedicines.
PEI requires blood centers to submit marketing authorization
applications (MAAs) in order to manufacture and distribute blood
products, including INTERCEPT platelets. The review period for new MAAs
can be up to 12 months following submission.

“Cerus’ German team is prepared to work with blood centers and hospitals
to educate clinicians about this new reimbursed treatment option, and
support the local marketing authorizations necessary to make INTERCEPT
more broadly available within the market,” continued Greenman.

In addition to enabling access to platelets with a reduced risk of
disease transmission, reimbursement is also expected to improve access
to increased shelf life for platelets. In 2008, the German National
Blood Advisory Committee (Arbeitskreis Blut, or AK Blut) advised the
German Ministry of Health that the shelf life of conventional platelet
components should be shortened to four days to reduce the incidence of
life-threatening septic transfusion reactions arising from potential
bacterial contamination. Only pathogen-inactivated platelets, such as
those treated with the INTERCEPT Blood System may be stored for five
days, without additional interventions to reduce the risk of sepsis. The
option to extend shelf life from four to five days is estimated to
reduce platelet wastage rates by as much as 15-20%.

Reimbursement rates for 2018 are published on the InEK website at:
http://www.g-drg.de/inek_site_en/G-DRG-System_2018/Fallpauschalen-Katalog/Fallpauschalen-Katalog_2018

ABOUT CERUS

Cerus Corporation is a biomedical products company focused in the field
of blood transfusion safety. The INTERCEPT Blood System is designed to
reduce the risk of transfusion-transmitted infections by inactivating a
broad range of pathogens such as viruses, bacteria and parasites that
may be present in donated blood. The nucleic acid targeting mechanism of
action of the INTERCEPT treatment is designed to inactivate established
transfusion threats, such as hepatitis B and C, HIV, West Nile virus and
bacteria, as well as emerging pathogens such as chikungunya, malaria and
dengue. Cerus currently markets and sells the INTERCEPT Blood System for
both platelets and plasma in the United States, Europe, the Commonwealth
of Independent States, the Middle East and selected countries in other
regions around the world. The INTERCEPT Red Blood Cell system is in
clinical development. See http://www.cerus.com
for information about Cerus.

This press release contains forward-looking statements. Any statements
contained in this press release that are not statements of historical
fact may be deemed to be forward-looking statements, including, without
limitation, statements regarding the expected impact of national
reimbursement on patient access to INTERCEPT platelets and the impact of
INTERCEPT platelets on platelet wastage rates. These forward-looking
statements are based upon Cerus’ current expectations. Actual results
could differ materially from these forward-looking statements as a
result of certain factors, including, without limitation, risks
associated with the commercialization, implementation and use of the
INTERCEPT Blood System, as well as other risks detailed in Cerus’
filings with the Securities and Exchange Commission, including Cerus’
Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, filed
with the SEC on August 4, 2017. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the
date of this press release. Cerus disclaims any obligation or
undertaking to update or revise any forward-looking statements contained
in this press release.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.

Contacts

Cerus Corporation
Tim Lee – Investor Relations Director
925-288-6137

Source: Cerus Corporation

Étiquettes :